Skip to content

A real world study for Yi-Qi Huo-Xue prescription in the treatment of angina pectoris of coronary heart disease

A real world study for Yi-Qi Huo-Xue prescription in the treatment of angina pectoris of coronary heart disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2000002967
Enrollment
Unknown
Registered
2020-02-04
Start date
2020-02-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Sponsors

Oriental Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Consistent with the diagnosis of coronary heart disease angina pectoris, with one of the following evidence: (1) There is a clear history of old myocardial infarction; (2) Coronary angiography, suggesting at least one coronary stenosis, and lumen stenosis >=50%; (3) CTA suggested stenosis of the main vascular lumen >= 50% (or above moderate stenosis); 2. Angina pectoris attacks >=2 times per week; 3. Meet the diagnostic criteria of qi deficiency and blood stasis; 4. Aged 30-75 years; 5. Voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Coronary revascularization was performed within 60 days; 2. Use any preparation of traditional Chinese medicine (such as proprietary Chinese medicine, Chinese medicine granule, etc.) in the recent month; 3. Acute myocardial infarction occurred in recent month; 4. Patients with one of the following diseases: (1) Patients with high blood pressure after hypertension and antihypertensive drug treatment (systolic blood pressure >= 180mmHg, diastolic blood pressure >=100mmHg); (2) Severe arrhythmia (atrial fibrillation with rapid ventricular response, atrial flutter, paroxysmal ventricular tachycardia, etc.), pulmonary heart disease, rheumatic heart disease, myocarditis, cardiomyopathy, aortic dissection, pulmonary embolism and other serious diseases; 5. Chest pain symptoms related to hyperthyroidism, cervical spondylosis, gallbladder heart syndrome, gastroesophageal reflux disease or hiatal hernia, neurosis, climacteric syndrome, etc.; 6. The upper limit of serum alanine transaminase or serum creatinine >2 times the normal reference value. 7. Severe hematological diseases. 8. Malignant tumor; 9. Women of child-bearing age who are pregnant or breast-feeding or who are required to have children; 10. Mental illness or cognitive dysfunction; 11. Allergic to the test drug; 12. Have participated in other clinical trials within the recent month.

Design outcomes

Primary

MeasureTime frame
response rate;

Secondary

MeasureTime frame
ECG;TCM score;TCM symptom score;Seattle Angina Questionnaire;Sf-36 quality of life scale;Angina score scale;

Countries

China

Contacts

Public ContactCui Xiaoyun

Oriental Hospital, Beijing University of Chinese Medicine

13811890290@126.com+86 13811890290

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026